Sign In
Buy RLAY
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
10:58am, Friday, 27'th Feb 2026
Casdin Capital bought 1,662,193 shares of Relay Therapeutics; the estimated trade size was $11.86 million. Meanwhile, the quarter-end position value rose by $50.81 million, reflecting both trading and
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
07:01pm, Thursday, 26'th Feb 2026
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.45 per share a year ago.
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
04:05pm, Thursday, 26'th Feb 2026
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
04:05pm, Monday, 23'rd Feb 2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
05:55pm, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
02:56pm, Friday, 06'th Feb 2026
Donald Bergstrom sold 21,581 shares over Jan. 27 and Jan. 28, 2026, generating a total value of approximately $166,700 at a weighted average price around $7.72 per share. This transaction reduced his
$207B Market Shift: The Race for Fast Track Approval in Oncology
09:35am, Thursday, 05'th Feb 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
04:05pm, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib
Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism
06:38am, Wednesday, 28'th Jan 2026
Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhi
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug
01:30pm, Friday, 12'th Dec 2025
Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in breast cancer patients.
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with P
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares
08:47am, Wednesday, 03'rd Dec 2025
New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period.
Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript
03:23am, Saturday, 22'nd Nov 2025
Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
04:05pm, Thursday, 06'th Nov 2025
Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commerc
